{"id":"dtg-abc-3tc","safety":{"commonSideEffects":[{"rate":"5-8","effect":"Hypersensitivity reaction (abacavir)"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Headache"},{"rate":"3-5","effect":"Insomnia"},{"rate":"2-5","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DTG (dolutegravir) is an integrase strand transfer inhibitor that blocks HIV integrase, preventing viral DNA from integrating into the host genome. ABC (abacavir) and 3TC (lamivudine) are nucleoside reverse transcriptase inhibitors that block the reverse transcriptase enzyme, preventing conversion of viral RNA to DNA. Together, these three agents provide complementary mechanisms to suppress HIV viral load.","oneSentence":"This is a fixed-dose combination of three antiretroviral drugs that work together to suppress HIV replication by inhibiting reverse transcriptase and integrase enzymes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:00.064Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced adults"},{"name":"HIV-1 infection in adolescents and children (weight-based formulations)"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT07001319","phase":"PHASE1","title":"Study of GS-3242 in Participants With HIV-1; Substudy-05","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-05-29","conditions":"HIV-1-infection","enrollment":30},{"nctId":"NCT05393193","phase":"PHASE4","title":"POC HIV Testing and Early DTG Use for Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2022-07-04","conditions":"HIV","enrollment":900},{"nctId":"NCT03016533","phase":"PHASE3","title":"Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2017-06-06","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT05122767","phase":"PHASE1, PHASE2","title":"Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2023-05-24","conditions":"Tuberculosis, HIV","enrollment":92},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT07115368","phase":"PHASE1","title":"Study of GS-1219 in Participants With HIV-1","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2025-08-11","conditions":"HIV-1-infection","enrollment":4},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT03360682","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2018-04-13","conditions":"HIV-1-infection, Solid Organ Transplant","enrollment":19},{"nctId":"NCT07138144","phase":"PHASE4","title":"Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up","status":"RECRUITING","sponsor":"José Antonio Mata Marín","startDate":"2025-07-12","conditions":"HIV Infections","enrollment":156},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT02284035","phase":"PHASE3","title":"Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2015-09-27","conditions":"AIDS","enrollment":75},{"nctId":"NCT05729568","phase":"PHASE2","title":"A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-15","conditions":"HIV Infection","enrollment":83},{"nctId":"NCT05193994","phase":"PHASE3","title":"Triumeq in Amyotrophic Lateral Sclerosis","status":"TERMINATED","sponsor":"Macquarie University, Australia","startDate":"2022-02-24","conditions":"Amyotrophic Lateral Sclerosis","enrollment":419},{"nctId":"NCT06658977","phase":"PHASE3","title":"RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial","status":"TERMINATED","sponsor":"Macquarie University, Australia","startDate":"2024-11-15","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":12},{"nctId":"NCT00796263","phase":"PHASE3","title":"Antiretroviral Therapy for Acute and Chronic HIV Infection","status":"RECRUITING","sponsor":"SEARCH Research Foundation","startDate":"2009-05-13","conditions":"Acute HIV Infection, Chronic HIV Infection","enrollment":900},{"nctId":"NCT05585307","phase":"PHASE1","title":"Study of Novel Antiretrovirals in Participants With HIV-1","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2022-10-26","conditions":"HIV-1-infection","enrollment":49},{"nctId":"NCT04034862","phase":"PHASE3","title":"Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs","status":"COMPLETED","sponsor":"University of Liege","startDate":"2019-10-01","conditions":"HIV Infections","enrollment":36},{"nctId":"NCT04012931","phase":"PHASE2","title":"A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-07-18","conditions":"HIV","enrollment":26},{"nctId":"NCT06629480","phase":"NA","title":"Incidence of Metabolic Syndrome in People Living With HIV Without ExperienCe to ART Who Start DoLutegravir Based-Regimen Compared With BictegrAvir Based-RegimeN","status":"COMPLETED","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2021-06-25","conditions":"Antiretroviral Treatment, HIV Infection, Metabolic Cardiovascular Syndrome","enrollment":378},{"nctId":"NCT06602622","phase":"PHASE4","title":"Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2024-08-14","conditions":"HIV, HIV Associate Weight Loss, HIV-1 Infection","enrollment":108},{"nctId":"NCT04493216","phase":"PHASE2","title":"A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2020-11-18","conditions":"HIV Infections","enrollment":161},{"nctId":"NCT04904406","phase":"PHASE4","title":"Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals","status":"COMPLETED","sponsor":"Thomas Benfield","startDate":"2020-10-22","conditions":"Hiv, HIV Infections, HIV Cardiomyopathy","enrollment":81},{"nctId":"NCT02659761","phase":"PHASE4","title":"Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs","status":"TERMINATED","sponsor":"University College Dublin","startDate":"2016-11","conditions":"Human Immunodeficiency Virus","enrollment":33},{"nctId":"NCT01910402","phase":"PHASE3","title":"A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2013-08-22","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":499},{"nctId":"NCT02486133","phase":"PHASE3","title":"Dual Therapy With Boosted Darunavir + Dolutegravir","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-07","conditions":"HIV-Infection","enrollment":269},{"nctId":"NCT04340388","phase":"PHASE4","title":"Contribution of Dolutegravir to Obesity and Cardiovascular Disease","status":"COMPLETED","sponsor":"Augusta University","startDate":"2020-09-17","conditions":"HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases","enrollment":10},{"nctId":"NCT03760458","phase":"PHASE1, PHASE2","title":"The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-09-09","conditions":"HIV Infections","enrollment":57},{"nctId":"NCT04827134","phase":"PHASE1","title":"A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2021-05-07","conditions":"HIV Infections","enrollment":33},{"nctId":"NCT03656783","phase":"PHASE3","title":"Effects of Biktarvy on CFR in Stable HIV Patients","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2018-09-14","conditions":"HIV","enrollment":25},{"nctId":"NCT02924389","phase":"PHASE4","title":"Dolutegravir in Reservoirs","status":"TERMINATED","sponsor":"Emory University","startDate":"2016-09","conditions":"HIV","enrollment":22},{"nctId":"NCT05351684","phase":"PHASE2","title":"Effect of Dolutegravir Intensification on HIV-1 Reservoirs","status":"COMPLETED","sponsor":"University of Liege","startDate":"2019-01-01","conditions":"HIV-1-infection","enrollment":20},{"nctId":"NCT02075593","phase":"PHASE3","title":"ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-12-17","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections, Arthralgia","enrollment":4},{"nctId":"NCT05525156","phase":"PHASE2","title":"The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy","status":"SUSPENDED","sponsor":"Muhimbili University of Health and Allied Sciences","startDate":"2020-03-02","conditions":"Hiv, Cardiovascular Diseases","enrollment":454},{"nctId":"NCT03685500","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2018-12-04","conditions":"HIV Infections","enrollment":78},{"nctId":"NCT05030025","phase":"EARLY_PHASE1","title":"Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2021-08-01","conditions":"HIV-1-infection","enrollment":43},{"nctId":"NCT02607930","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-13","conditions":"HIV-1 Infection","enrollment":631},{"nctId":"NCT02384395","phase":"NA","title":"Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2015-09","conditions":"HIV, Acute HIV Infection","enrollment":40},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT03447873","phase":"PHASE4","title":"Tripe Versus Dual Antiretroviral Therapy in HIV-infected Patients With Virological Suppression (Tridual)","status":"COMPLETED","sponsor":"Hospitales Universitarios Virgen del Rocío","startDate":"2017-06-01","conditions":"HIV Infections","enrollment":153},{"nctId":"NCT03602690","phase":"PHASE2","title":"Evaluation of Third-line cART Regimen in Cambodia (3DICAM)","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2018-10-04","conditions":"HIV/AIDS","enrollment":54},{"nctId":"NCT02569346","phase":"PHASE1","title":"Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2016-03","conditions":"HIV","enrollment":22},{"nctId":"NCT02603120","phase":"PHASE3","title":"Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT04600687","phase":"NA","title":"B/F/TAF Ease of Swallowability Trial","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2018-11-06","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT03067285","phase":"PHASE4","title":"A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2017-09-08","conditions":"HIV Infections","enrollment":39},{"nctId":"NCT04155554","phase":"PHASE3","title":"Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Senese","startDate":"2020-01-29","conditions":"HIV-1-infection","enrollment":100},{"nctId":"NCT03441984","phase":"PHASE1","title":"To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-02-26","conditions":"HIV Infections","enrollment":36},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT03224338","phase":"PHASE2","title":"Dolutegravir Plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Subjects","status":"COMPLETED","sponsor":"Blueclinical, Ltd.","startDate":"2017-04-05","conditions":"HIV II Infection","enrollment":30},{"nctId":"NCT02868580","phase":"PHASE2","title":"Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).","status":"COMPLETED","sponsor":"Neuroscience Trials Australia","startDate":"2016-10","conditions":"Amyotrophic Lateral Sclerosis","enrollment":43},{"nctId":"NCT02342769","phase":"","title":"Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-02-19","conditions":"HIV Infections","enrollment":403},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT02596334","phase":"PHASE3","title":"Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients","status":"TERMINATED","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2015-12-23","conditions":"HIV","enrollment":158},{"nctId":"NCT01227824","phase":"PHASE3","title":"A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-10-19","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":828},{"nctId":"NCT02337322","phase":"PHASE4","title":"Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir","status":"UNKNOWN","sponsor":"Juan A. Arnaiz","startDate":"2015-03-31","conditions":"Acquired Immune Deficiency Syndrome Virus","enrollment":104},{"nctId":"NCT01263015","phase":"PHASE3","title":"A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-02-01","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":844},{"nctId":"NCT02509195","phase":"PHASE4","title":"SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-08-04","conditions":"HIV","enrollment":40},{"nctId":"NCT03256422","phase":"PHASE3","title":"Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2017-09-07","conditions":"HIV Infections","enrollment":640},{"nctId":"NCT00951015","phase":"PHASE2","title":"A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-07-30","conditions":"Infection, Human Immunodeficiency Virus","enrollment":208},{"nctId":"NCT01449929","phase":"PHASE3","title":"Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-10-31","conditions":"Infection, Human Immunodeficiency Virus","enrollment":488},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":"HIV-DDI","enrollment":40},{"nctId":"NCT03275701","phase":"NA","title":"Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC","status":"UNKNOWN","sponsor":"Mills Clinical Research","startDate":"2016-07","conditions":"Infection, Human Immunodeficiency Virus","enrollment":50},{"nctId":"NCT02893488","phase":"PHASE1","title":"Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-09-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":20},{"nctId":"NCT02513147","phase":"PHASE4","title":"HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-06","conditions":"HIV-1","enrollment":44},{"nctId":"NCT02738931","phase":"PHASE1","title":"Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-05","conditions":"Infection, Human Immunodeficiency Virus","enrollment":30},{"nctId":"NCT02105987","phase":"PHASE3","title":"A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04","conditions":"Infection, Human Immunodeficiency Virus","enrollment":555},{"nctId":"NCT02588820","phase":"PHASE3","title":"Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection","status":"UNKNOWN","sponsor":"David Garcia Cinca","startDate":"2016-04","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT02067767","phase":"PHASE2","title":"Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD)","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2014-02","conditions":"HIV-1 Infection","enrollment":53},{"nctId":"NCT02539576","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-10","conditions":"Infection, Human Immunodeficiency Virus","enrollment":12},{"nctId":"NCT01966822","phase":"PHASE3","title":"Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2014-01","conditions":"HIV-1 Infection","enrollment":75},{"nctId":"NCT01499199","phase":"PHASE3","title":"A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":13},{"nctId":"NCT02285374","phase":"PHASE4","title":"Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity","status":"UNKNOWN","sponsor":"St Stephens Aids Trust","startDate":"2014-11","conditions":"HIV","enrollment":40},{"nctId":"NCT01622790","phase":"PHASE1","title":"Evaluation of the Bioequivalence of a Combined Formulated Tablet","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-06","conditions":"Infection, Human Immunodeficiency Virus","enrollment":66},{"nctId":"NCT01366547","phase":"PHASE1","title":"Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-06","conditions":"Healthy Subjects, Infection, Human Immunodeficiency Virus","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":63,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"DTG/ABC/3TC","genericName":"DTG/ABC/3TC","companyName":"Harvard School of Public Health (HSPH)","companyId":"harvard-school-of-public-health-hsph","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a fixed-dose combination of three antiretroviral drugs that work together to suppress HIV replication by inhibiting reverse transcriptase and integrase enzymes. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based formulations).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}